Himachal Pradesh’s State Drug Controller Manish Kapoor announced that 47 medicine samples failed quality tests and companies have been ordered to recall their stocks. Out of 200 samples tested across India, 47 came from Himachal Pradesh, including medicines for fever, heart attacks, and diabetes. These failed samples came from Solan (28), Sirmaur (18), and Una (1) districts. Notices have been served to the companies responsible. In November 2025, the Central Drugs Standard Control Organisation (CDSCO) collected 65 samples, and the State Drug Controller took 135 samples. Out of these 200, 47 were substandard. Mr. Kapoor said, "Notices have been issued to the companies whose medicine samples failed the quality tests. They have also been asked to recall the stock from the market." He added, "Explanations have been sought, and actions will be taken against the companies in accordance with regulations." The failed medicines include Paracetamol for fever, Clopidogrel and Aspirin for heart attacks, Metformin for diabetes, Ramipril for heart conditions, Sodium Valproate for epilepsy, and Mebeverine Hydrochloride for muscle spasms. Health Minister Dhani Ram Shandil earlier warned that companies repeatedly failing quality tests would face blacklisting. The government has been actively acting against such firms. A March 2025 alert from the central drug regulator had already reported 38 substandard drug samples from the state. This ongoing trend has raised concerns about medicine quality in Himachal Pradesh.